Colleen Egan, Clinical Drug Trial Registry Could Have Mixed Results for Drug Industry, iHealth, October 5, 2004. Excerpt: "A high-stakes battle is raging in Congress as pharmaceutical companies, legislators and citizens debate whether drug makers should be required to fully disclose the results of clinical drug trials on the Internet.....Peter Suber, open access project director for advocacy group Public Knowledge, said that the main benefit to posting drug trial information online is to make the negative outcomes as prominent as the positive outcomes, which Suber said should help neutralize what he called the one-sided information presented in ads and scientific journals. While it may not be realistic for patients to go online and pore through dense drug studies, Suber said patients will at least indirectly benefit from the availability of the information to researchers and their physicians.....'Once the data are freely available online, I wouldn't be surprised to see data-mining tools emerge for their exploration and analysis,' Suber said. 'These tools will...bring the data to groups that wouldn't have had much use for them before, such as students, and increase the data's utility for the groups that had been making routine use of them.' "
Posted by
Peter Suber at 10/05/2004 01:45:00 PM.
The open access movement:
Putting peer-reviewed scientific and scholarly literature
on the internet. Making it available free of charge and
free of most copyright and licensing restrictions.
Removing the barriers to serious research.
I recommend the OA tracking project (OATP) as the best way to stay on top of new OA developments. You can read the OATP feed on a blog-like web page or subscribe to it by RSS, email, or Twitter. You can also help build the feed by tagging new developments you encounter.
